First-trimester screening and its impact on uptake of diagnostic testing

被引:3
作者
Darnes, Deanna R. [1 ]
Hashmi, Syed [1 ]
Monga, Manju [2 ]
Sullivan, Cathy [2 ]
Vidaeff, Alex [2 ]
Berens, Pamela [2 ]
Czerwinski, Jennifer L. [2 ]
机构
[1] Univ Texas Houston Med Sch, Dept Pediat, Houston, TX USA
[2] Univ Texas Houston Med Sch, Dept Obstet & Gynecol, Houston, TX USA
关键词
first-trimester screening; influence; diagnostic testing; uptake; HUMAN CHORIONIC-GONADOTROPIN; FETAL NUCHAL TRANSLUCENCY; MATERNAL AGE;
D O I
10.1002/pd.2800
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Objective To determine the influence of first-trimester screening (FTS) on a patient's decision regarding prenatal diagnostic testing (PDT) and if the uptake rate of PDT has changed among women with advanced maternal age (AMA) following the January 2007 American College of Obstetricians and Gynecologists statement regarding FTS. Methods A database review was performed for the 2 years before and the 2 years after the January statement. A total of 7424 patient records were evaluated to determine the number of AMA women who obtained PDT, the number of positive and negative FTS results, and how many of those women had PDT. We then surveyed 53 patients and 23 referring physicians to determine what the patient understands about FTS, how patients utilize their FTS results, and how physicians educate their patients about FTS. Results We determined that there was a 19.6% decrease in the uptake of PDT since that statement. Prior to their counseling session (2009-2010), 43% of those surveyed were against having PDT. After counseling, only 9% were against PDT. Overall, 91% were either open to or wanted PDT after counseling. Conclusions In addition to FTS results, we found that genetic counseling may be an influential factor in the patient's decision regarding PDT. Copyright (C) 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:892 / 896
页数:5
相关论文
共 16 条
[1]  
ACOG, 2007, OBSTET GYNECOL, V110, P1459
[2]  
[Anonymous], 2007, Obstetrics Gynecology, V109, P217
[3]   Is nuchal translucency screening associated with different rates of invasive testing in an older obstetric population? [J].
Chasen, ST ;
McCullough, LB ;
Chervenak, FA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 190 (03) :769-774
[4]   SURVEY OF MONGOLOID BIRTHS IN VICTORIA, AUSTRALIA, 1942-1957 [J].
COLLMANN, RD ;
STOLLER, A .
AMERICAN JOURNAL OF PUBLIC HEALTH AND THE NATIONS HEALTH, 1962, 52 (05) :813-+
[5]   Is routine amniocentesis for advanced maternal age still indicated? [J].
Dommergues, M ;
Audibert, F ;
Benattar, C ;
Champagne, C ;
Gomel, V ;
Frydman, R .
FETAL DIAGNOSIS AND THERAPY, 2001, 16 (06) :372-377
[6]   First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: A population-based screening study (The FASTER Trial) [J].
Dugoff, L ;
Hobbins, JC ;
Malone, FD ;
Porter, TF ;
Luthy, D ;
Comstock, CH ;
Hankins, G ;
Berkowitz, RL ;
Merkatz, I ;
Craigo, SD ;
Timor-Tritsch, IE ;
Carr, SR ;
Wolfe, HM ;
Vidaver, J ;
D'Alton, ME .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 191 (04) :1446-1451
[7]   Screening advances and diagnostic choice: The problem of residual risk [J].
Henry, George P. ;
Britt, David W. ;
Evans, Mark I. .
FETAL DIAGNOSIS AND THERAPY, 2008, 23 (04) :308-315
[8]  
Hook E B, 1977, Birth Defects Orig Artic Ser, V13, P123
[9]   Screening for trisomy 18 by maternal age, fetal nuchal translucency, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A [J].
Kagan, K. O. ;
Wright, D. ;
Maiz, N. ;
Pandeva, I. ;
Nicolaides, K. H. .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2008, 32 (04) :488-492
[10]   Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A [J].
Kagan, K. O. ;
Wright, D. ;
Baker, A. ;
Sahota, D. ;
Nicolaides, K. H. .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2008, 31 (06) :618-624